Evoke Pharma Surges on Notice of Patent Allowance for Gimoti

Dow Jones

2025/07/10

By Josh Beckerman

Evoke Pharma shares surged after the company received a notice of allowance for a U.S. patent application for Gimoti extending Orange Book listings to 2036.

The stock was up 154% to $6.75 Wednesday, with an intraday high of $9.88. The stock is up over 50% this year. Volume was roughly 124 million shares as of early-afternoon trading, compared with a 90-day average of about 19,000.

Gimoti is a nasal spray for relief of symptoms associated with acute and recurrent diabetic gastroparesis.

Evoke said the allowed application is a continuation of U.S. Patent No. 11,517,545, and that it further expands Evoke's intellectual property estate around intranasal metoclopramide. The company said it has filed another U.S. continuation application to pursue additional claims.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

July 09, 2025 13:46 ET (17:46 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2550657544"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2550657544\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2550657544?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-10 01:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550657544","market":"nz","top_or_hot":-1,"title":"Evoke Pharma Surges on Notice of Patent Allowance for Gimoti","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/EVOK\">Evoke Pharma</a> shares surged after the company received a notice of allowance for a U.S. patent application for Gimoti extending <a href=\"https://laohu8.com/S/FNCTF\">Orange</a> Book listings to 2036. \n</p>\n<p>\n  The stock was up 154% to $6.75 Wednesday, with an intraday high of $9.88. The stock is up over 50% this year. Volume was roughly 124 million shares as of early-afternoon trading, compared with a 90-day average of about 19,000. \n</p>\n<p>\n  Gimoti is a nasal spray for relief of symptoms associated with acute and recurrent diabetic gastroparesis. \n</p>\n<p>\n  Evoke said the allowed application is a continuation of U.S. Patent No. 11,517,545, and that it further expands Evoke's intellectual property estate around intranasal metoclopramide. The company said it has filed another U.S. continuation application to pursue additional claims. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 09, 2025 13:46 ET (17:46 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evoke Pharma Surges on Notice of Patent Allowance for Gimoti</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvoke Pharma Surges on Notice of Patent Allowance for Gimoti\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-07-10 01:46</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/EVOK\">Evoke Pharma</a> shares surged after the company received a notice of allowance for a U.S. patent application for Gimoti extending <a href=\"https://laohu8.com/S/FNCTF\">Orange</a> Book listings to 2036. \n</p>\n<p>\n  The stock was up 154% to $6.75 Wednesday, with an intraday high of $9.88. The stock is up over 50% this year. Volume was roughly 124 million shares as of early-afternoon trading, compared with a 90-day average of about 19,000. \n</p>\n<p>\n  Gimoti is a nasal spray for relief of symptoms associated with acute and recurrent diabetic gastroparesis. \n</p>\n<p>\n  Evoke said the allowed application is a continuation of U.S. Patent No. 11,517,545, and that it further expands Evoke's intellectual property estate around intranasal metoclopramide. The company said it has filed another U.S. continuation application to pursue additional claims. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 09, 2025 13:46 ET (17:46 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2550657544","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550657544","pubTimestamp":1752083160,"columns":[{"name":"產品發布","id":31,"label_key":"productRelease"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Evoke Pharma shares surged after the company received a notice of allowance for a U.S. patent application for Gimoti extending Orange Book listings to 2036.The stock was up 154% to $6.75 Wednesday, with an intraday high of $9.88. The stock is up over 50% this year. Volume was roughly 124 million shares as of early-afternoon trading, compared with a 90-day average of about 19,000.Gimoti is a nasal spray for relief of symptoms associated with acute and recurrent diabetic gastroparesis.Evoke said the allowed application is a continuation of U.S. Patent No. 11,517,545, and that it further expands Evoke's intellectual property estate around intranasal metoclopramide. The company said it has filed another U.S. continuation application to pursue additional claims.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","EVOK":"Evoke Pharma Inc."},"translate_title":"Evoke Pharma因Gimoti专利许可通知而股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EVOK":1},"content_text":"By Josh Beckerman \n\n\n \n\n\nEvoke Pharma shares surged after the company received a notice of allowance for a U.S. patent application for Gimoti extending Orange Book listings to 2036. \n\n\n  The stock was up 154% to $6.75 Wednesday, with an intraday high of $9.88. The stock is up over 50% this year. Volume was roughly 124 million shares as of early-afternoon trading, compared with a 90-day average of about 19,000. \n\n\n  Gimoti is a nasal spray for relief of symptoms associated with acute and recurrent diabetic gastroparesis. \n\n\n  Evoke said the allowed application is a continuation of U.S. Patent No. 11,517,545, and that it further expands Evoke's intellectual property estate around intranasal metoclopramide. The company said it has filed another U.S. continuation application to pursue additional claims. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 09, 2025 13:46 ET (17:46 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}